Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease

Tariq E. Farrah, Atul Anand, Peter J. Gallacher, Robert Kimmitt, Edwin Carter, James W. Dear, Nicholas L. Mills, David J. Webb, Neeraj Dhaun*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease'. Together they form a unique fingerprint.

Medicine & Life Sciences